Thyroid, Brain and Mood Modulation in Affective Disorder: Insights from Molecular Research and Functional Brain Imaging

 

 Buy Article Permissions and Reprints

The efficacy resulting from adjunctive use of supraphysiological doses of levothyroxine has emerged as a promising approach to therapy and prophylaxis for refractory mood disorders. Most patients with mood disorders who receive treatment with supraphysiological doses of levothyroxine have normal peripheral thyroid hormone levels, and also respond differently to the hormone and tolerate it better than healthy individuals and patients with primary thyroid diseases. Progress in molecular and functional brain imaging techniques has provided a new understanding of these phenomena, illuminating the relationship between thyroid function, mood modulation and behavior.

Thyroid hormones are widely distributed in the brain and have a multitude of effects on the central nervous system. Notably many of the limbic system structures where thyroid hormone receptors are prevalent have been implicated in the pathogenesis of mood disorders. The influence of the thyroid system on neurotransmitters (particularly serotonin and norepinephrine), which putatively play a major role in the regulation of mood and behavior, may contribute to the mechanisms of mood modulation. Recent functional brain imaging studies using positron emission tomography (PET) with [¹⁸F]-fluorodeoxyglucose demonstrated that thyroid hormone treatment with levothyroxine affects regional brain metabolism in patients with hypothyroidism and bipolar disorder. Theses studies confirm that thyroid hormones are active in modulating metabolic function in the mature adult brain, and provide intriging neuroanatomic clues that may guide future research.

Reference

• 1 Altshuler L, Bauer M, Frye M, Gitlin M, Mintz J, Szuba M P, Leight K L, Whybrow P C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature.  Am J Psychiatr. 2001;  158 1617-1622
  CrossrefPubMedGoogle Scholar
• 2 Anderson G W, Mariash C N, Oppenheimer J H. Molecular actions of thyroid hormone. In: Braverman LE, Utiger RD, eds Werner & Ingbar’s The Thyroid. A Fundamental and Clinical Text. 8th ed Philadelphia; Lippincott Williams & Wilkins 2000: 174-195
  Google Scholar
• 3 Aronson R, Offman H J, Joffe R T, Naylor D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.  Arch Gen Psychiatry. 1996;  53 842-848
  CrossrefPubMedGoogle Scholar
• 4 Bauer M, Adli M, Bschor T, Heinz A, Rasgon N, Frye M, Grunze H, Kupka R, Whybrow P C. Clinical applications of levothyroxine in refractory mood disorders.  Clin Appl Bipolar Disord. 2003;  2 49-56
  PubMedGoogle Scholar
• 5 Bauer M, Baur H, Berghöfer A, Ströhle A, Hellweg R, Müller-Oerlinghausen B, Baumgartner A. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders.  J Affect Disord. 2002;  68 285-294
  CrossrefPubMedGoogle Scholar
• 6 Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Müller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders.  Neuropsychopharmacol. 2002;  27 620-628
  PubMedGoogle Scholar
• 7 Bauer M, Fairbanks L, Berghöfer A, Hierholzer J, Bschor T, Rasgon N, Whybrow P C. No evidence of accelerated loss of bone density during maintenance treatment with supraphysiological doses of L-thyroxine in prophylaxis-resistant affective disorders. Submitted manuscript. 
  Google Scholar
• 8 Bauer M, Heinz A, Whybrow P C. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain.  Mol Psychiatr. 2002;  7 140-156
  CrossrefPubMedGoogle Scholar
• 9 Bauer M, Hellweg R, Gräf K J, Baumgartner A. Treatment of refractory depression with high-dose thyroxine.  Neuropsychopharmacol. 1998;  18 444-455
  CrossrefPubMedGoogle Scholar
• 10 Bauer M, London E D, Rasgon N, Berman S M, Frye M A, Altshuler L, Mandelkern M A, Bramen J, Woods R, Mazziotta J C, Whybrow P C. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in women with bipolar depression. Submitted manuscript. 
  Google Scholar
• 11 Bauer M, Marseille D M, Geist C L, Van Herle K, Rasgon N, Martinez D, Miller K J, Haselrig T, Van Herle A J, Whybrow P C, Czernin J, Phelps M E, Silverman D HS. Effects of thyroid hormone replacement therapy on regional brain metabolism (abstract).  J Nucl Med. 2002;  43 (5, suppl) 254P
  PubMedGoogle Scholar
• 12 Bauer M, Priebe S, Berghöfer A, Bschor T, Kiesslinger K, Whybrow P C. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders.  J Affect Disord. 2001;  64 35-42
  CrossrefPubMedGoogle Scholar
• 13 Bauer M, Szuba M P, Whybrow P C. Psychiatric and behavioral manifestations of hyper- and hypothyroidism. In: Wolkowitz OM, Rothschild TJ (eds.) Psychoneuroendocrinology: The Scientific Basis of Clinical Practice. American Psychiatric Press, Inc Washington D.C; 2003: 419-444
  Google Scholar
• 14 Bauer M, Whybrow P C. Thyroid hormone, brain, and behavior. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds Hormones, Brain and Behavior. San Diego; Academic Press 2002: 238-264
  Google Scholar
• 15 Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation.  World J Biol Psychiatr. 2001;  2 57-67
  PubMedGoogle Scholar
• 16 Bauer M S, Whybrow P C, Winokur A. Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism.  Arch Gen Psychiatr. 1990;  47 427-432
  PubMedGoogle Scholar
• 17 Bauer M S, Whybrow P C. Rapid cycling bipolar affective disorders. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.  Arch Gen Psychiatr. 1990;  47 435-440
  CrossrefPubMedGoogle Scholar
• 18 Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research.  Int J Neuropsychopharmacol. 2000;  3 149-165
  PubMedGoogle Scholar
• 19 Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial.  Neuropsychopharmacol. 1994;  10 183-189
  PubMedGoogle Scholar
• 20 Beierwaltes W H, Ruff G E. Thyroxin and triiodothyronine in excessive dosage to euthyroid humans.  Arch Intern Med. 1958;  101 569-576
  PubMedGoogle Scholar
• 21 Braverman L E, Vagenakis A, Downs P, Foster A E, Sterling K, Ingbar S H. Effects of replacement doses of sodium-L-thyroxine on the peripheral metabolism of thyroxine and triiodothyronine in man.  J Clin Invest. 1973;  52 1010-1017
  PubMedGoogle Scholar
• 22 Brody A L, Barsom M W, Bota R G, Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder.  Semin Clin Neuropsychiatr. 2001;  6 102-112
  CrossrefPubMedGoogle Scholar
• 23 Calza L, Aloe L, Giardino L. Thyroid hormone-induced plasticity in the adult rat brain.  Brain Res Bull. 1997;  44 549-557
  CrossrefPubMedGoogle Scholar
• 24 Clinical Society of L ondon. Report on myxedema. Trans Clin Soc Lond (suppl) 1888 21: 18
  Google Scholar
• 25 Cohen JH 3 d, Ingbar S H, Braverman L E. Thyrotoxicosis due to ingestion of excess thyroid hormone.  Endocr Rev. 1989;  10 113-124
  PubMedGoogle Scholar
• 26 Cole D P, Thase M E, Mallinger A G, Soares J C, Luther J F, Kupfer D J, Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function.  Am J Psychiatr. 2002;  159 116-121
  CrossrefPubMedGoogle Scholar
• 27 Constant E L, de Volder A G, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J, Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study.  J Clin Endocrinol Metab. 2001;  86 3864-3870
  CrossrefPubMedGoogle Scholar
• 28 Drevets W C, Price J L, Simpson Jr J R, Todd R D, Reich T, Vannier M, Raichle M E. Subgenual prefrontal cortex abnormalities in mood disorders.  Nature. 1997;  386 824-827
  CrossrefPubMedGoogle Scholar
• 29 Drevets W C. Neuroimaging studies of mood disorders.  Biol Psychiatr. 2000;  48 813-29
  CrossrefPubMedGoogle Scholar
• 30 Flach F F, Celian C I, Rawson R W. Treatment of psychiatric disorders with triiodothyronine.  Am J Psychiatry. 1958;  114 841-842
  PubMedGoogle Scholar
• 31 Frye M A, Denicoff K D, Bryan A L, Smith-Jackson E E, Ali S O, Luckenbaugh D, Leverich G S, Post R M. Association between lower serum free T₄ and greater mood instability and depression in lithium-maintained bipolar patients.  Am J Psychiatr. 1999;  156 1909-1914
  PubMedGoogle Scholar
• 32 Gjessing R. Disturbances of somatic function in catatonia with a periodic course and their compensation.  J Ment Sci. 1938;  84 608-621
  PubMedGoogle Scholar
• 33 Gyulai L, Bauer M, Espana-Garcia F, Hierholzer J, Baumgartner A, Whybrow P C. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.  J Affect Disord. 2001;  66 185-191
  CrossrefPubMedGoogle Scholar
• 34 Gyulai L, Whybrow P C, Jaggi J, Bauer M S, Younkin S, Rubin L, Attie M. Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder.  Biol Psychiatr. 1997;  41 503-506
  CrossrefPubMedGoogle Scholar
• 35 Gyulai L, Bauer M, Bauer M S, García-España F, Cnaan A, Whybrow P C. Thyroid hypofunction in patients with rapid cycling bipolar disorder after lithium challenge.  Biol Psychiatry. 2003;  53 899-905
  CrossrefPubMedGoogle Scholar
• 36 Henley W N, Koehnle T J. Thyroid hormones and the treatment of depression: An examination of basic hormonal actions in the mature mammalian brain.  Synapse. 1997;  27 36-44
  CrossrefPubMedGoogle Scholar
• 37 Ketter T A, Kimbrell T A, George M S, Dunn R T, Speer A M, Benson B E, Willis M W, Danielson A, Frye M A, Herscovitch P, Post R M. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder.  Biol Psychiatr. 2001;  49 97-109
  CrossrefPubMedGoogle Scholar
• 38 Köhrle J. Thyroid hormone metabolism and action in the brain and pituitary.  Acta Med Austriaca. 2000;  27 1-7
  PubMedGoogle Scholar
• 39 Lechan R M, Toni R. Thyroid hormones in neural tissue. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds Hormones, Brain and Behavior. San Diego; Academic Press 2002: 157-238
  Google Scholar
• 40 Leonard J L, Koehrle J. Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds Werner & Ingbar’s The Thyroid. A Fundamental and Clinical Text. 8th ed Philadelphia; Lippincott Williams & Wilkins 2000: 136-171
  Google Scholar
• 41 Marangell L B, Ketter T A, George M S, Pazzaglia P J, Callahan A M, Parekh P, Andreason P J, Horwitz B, Herscovitch P, Post R M. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders.  Am J Psychiatr. 1997;  154 224-230
  PubMedGoogle Scholar
• 42 Minoshima S, Giordani B, Berent S, Frey K A, Foster N L, Kuhl D E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease.  Ann Neurol. 1997;  42 85-94
  CrossrefPubMedGoogle Scholar
• 43 Prange AJ J r, Wilson I C, Rabon A M, Lipton M A. Enhancement of imipramine antidepressant activity by thyroid hormone.  Am J Psychiatry. 1969;  126 457-469
  PubMedGoogle Scholar
• 44 Refetoff S. Resistance to thyroid hormone. In: Braverman LE, Utiger RD, eds Werner & Ingbar’s The Thyroid. A Fundamental and Clinical Text. 8th ed Philadelphia; Lippincott Williams & Wilkins 2000: 1028-1043
  Google Scholar
• 45 Reichlin S, Utiger R D. Regulation of the pituitary-thyroid axis in man: relationship of TSH concentration to concentration of free and total thyroxine in plasma.  J Clin Endocrinol Metab. 1967;  27 251-255
  CrossrefPubMedGoogle Scholar
• 46 Robbins J. Transthyretin from discovery to now.  Clin Chem Lab Med. 2002;  40 1183-1190
  CrossrefPubMedGoogle Scholar
• 47 Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine.  Biol Psychiatr. 1999;  2 229-233
  PubMedGoogle Scholar
• 48 Ruel J, Faure R, Dussault J H. Regional distribution of nuclear T3 receptors in rat brain and evidence for preferential localization in neurons.  J Endocrinol Invest. 1985;  8 343-348
  PubMedGoogle Scholar
• 49 Schwartz H L, Oppenheimer J H. Nuclear triiodothyronine receptor sites in brain: probable identity with hepatic receptors and regional distribution.  Endocrinol. 1978;  103 267-273
  PubMedGoogle Scholar
• 50 Sensenbach W, Madison L, Eisenberg S, Ochs L. The cerebral circulation and metabolism in hyperthyroidism and myxedema.  J Clin Invest. 1954;  33 1434-1440
  PubMedGoogle Scholar
• 51 Silverman D HS, Geist C L, Van Herle K, Rasgon N, Martinez D, Miller K J, Haselrig T, Van Herle A J, Whybrow P C, Czernin J, Phelps M E, Bauer M. Abnormal regional brain metabolism in patients with hypothyroidism secondary to Hashimoto’s disease (abstract).  J Nucl Med. 2002;  43 (5, suppl) 254P
  PubMedGoogle Scholar
• 52 Sokoloff L, Wechsler R L, Mangold R, Balls K, Kety S S. Cerebral blood flow and oxygen consumption in hyperthyroidism before and after treatment.  J Clin Invest. 1953;  32 202-208
  PubMedGoogle Scholar
• 53 Stancer H C, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine.  Arch Gen Psychiatr. 1982;  39 311-312
  PubMedGoogle Scholar
• 54 Sullivan G M, Hatterer J A, Herbert J, Chen X, Roose S P, Attia E, Mann J J, Marangell L B, Goetz R R, Gorman J M. Low levels of transthyretin in the CSF of depressed patients.  Am J Psychiatry. 1999;  156 710-715
  PubMedGoogle Scholar
• 55 Toft A D. Thyroxine therapy.  N Engl J Med. 1994;  331 174-180
  CrossrefPubMedGoogle Scholar
• 56 Whybrow P C, Bauer M. Behavioral and psychiatric aspects of hypothyroidism. In: Braverman LE, Utiger RD, eds Werner & Ingbar’s The Thyroid. A Fundamental and Clinical Text. 8th ed Philadelphia; Lippincott Williams & Wilkins 2000: 837-842
  Google Scholar
• 57 Whybrow P C, Bauer M. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Utiger RD, eds Werner & Ingbar’s The Thyroid. A Fundamental and Clinical Text. 8th ed Philadelphia; Lippincott Williams & Wilkins 2000: 673-678
  Google Scholar
• 58 Whybrow P C, Prange AJ J r. A hypothesis of thyroid-catecholamine-receptor interaction.  Arch Gen Psychiatr. 1981;  38 106-113
  PubMedGoogle Scholar
• 59 Whybrow P C, Prange AJ J r, Treadway C R. Mental changes accompanying thyroid gland dysfunction.  Arch Gen Psychiatry. 1969;  20 48-63
  CrossrefPubMedGoogle Scholar
• 60 Whybrow P C. The therapeutic use of triiodothyronine and high-dose thyroxine in psychiatric disorder.  Acta med Austriaca. 1994;  21 47-52
  PubMedGoogle Scholar
• 61 Whybrow P C. Sex differences in thyroid axis function: Relevance to affective disorder and its treatment.  Depression. 1995;  3 33-42
  PubMedGoogle Scholar
• 62 Wilson I C, Prange AJ J r, Lara P P. L-Triiodothyronine alone and with imipramine in the treatment of depressed women. In: Prange AJ Jr (ed.) The Thyroid Axis, Drugs, and Behavior. Raven Press New York; 1974: 49-62
  Google Scholar

Michael Bauer, M.D., Ph. D.

Department of Psychiatry and Psychotherapy

Charité - University Medicine Berlin

Campus Charité-Mitte (CCM)

Schumannstr. 20/21

10117 Berlin

Germany

Phone: +49-30-450 51 70 70

Fax: +49-30-450-51 79 62

Email: michael.bauer@charite.de